NLS Total Assets from 2010 to 2024

NLSPW Stock

USD 0.01 0 18.18%

NLS Pharmaceutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

1.8 M

Current Value

3.3 M

Quarterly Volatility

2.2 M

Credit Downgrade

Yuan Drop

Covid

Check NLS Pharmaceutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NLS Pharmaceutics' main balance sheet or income statement drivers, such as Interest Income of 681.3 K, Depreciation And Amortization of 9.8 K or Interest Expense of 137.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NLS financial statements analysis is a perfect complement when working with NLS Pharmaceutics Valuation or Volatility modules.

Check out the analysis of NLS Pharmaceutics Correlation against competitors.

Latest NLS Pharmaceutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of NLS Pharmaceutics AG over the last few years. Total assets refers to the total amount of NLS Pharmaceutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NLS Pharmaceutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. NLS Pharmaceutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NLS Pharmaceutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.85 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

NLS Total Assets Regression Statistics

	Arithmetic Mean	2,705,540
	Geometric Mean	1,990,120
	Coefficient Of Variation	81.39
	Mean Deviation	1,368,113
	Median	2,288,169
	Standard Deviation	2,202,083
	Sample Variance	4.8T
	Range	9.1M
	R-Value	0.33
	Mean Square Error	4.7T
	R-Squared	0.11
	Significance	0.24
	Slope	160,640
	Total Sum of Squares	67.9T

NLS Total Assets History

	2024	3.3 M
	2023	1.8 M
	2022	9.3 M
	2021	5.8 M
	2020	1.2 M
	2019	696.4 K
	2018	145.6 K

Other Fundumenentals of NLS Pharmaceutics

Intangibles To Total Assets

NLS Pharmaceutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Capital Surpluse	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Net Receivables	Short Long Term Debt	Capital Stock	Short Term Debt	Current Deferred Revenue
Total Assets		0.89	-0.78	-0.46	0.07	-0.33	0.3	-0.63	0.42	0.99	0.61	0.53	0.13	0.46	0.6	0.38	0.51
Total Stockholder Equity	0.89		-0.82	-0.31	0.06	-0.39	0.4	-0.73	0.42	0.89	0.63	0.32	0.39	0.39	0.47	0.55	0.43
Net Debt	-0.78	-0.82		0.74	-0.58	0.84	-0.82	0.81	0.15	-0.73	-0.1	-0.69	-0.59	-0.77	-0.75	-0.48	-0.8
Retained Earnings	-0.46	-0.31	0.74		-0.79	0.82	-0.8	0.5	0.54	-0.44	0.35	-0.98	-0.19	-0.82	-0.92	-0.17	-0.85
Accounts Payable	0.07	0.06	-0.58	-0.79		-0.88	0.91	-0.22	-0.82	0.0	-0.69	0.65	0.53	0.85	0.67	0.03	0.83
Long Term Debt	-0.33	-0.39	0.84	0.82	-0.88		-0.98	0.66	0.66	-0.26	0.46	-0.69	-0.69	-0.82	-0.67	-0.32	-0.84
Capital Surpluse	0.3	0.4	-0.82	-0.8	0.91	-0.98		-0.56	-0.65	0.24	-0.44	0.67	0.68	0.85	0.71	0.32	0.86
Total Liab	-0.63	-0.73	0.81	0.5	-0.22	0.66	-0.56		0.05	-0.61	-0.18	-0.47	-0.5	-0.36	-0.39	-0.57	-0.43
Net Invested Capital	0.42	0.42	0.15	0.54	-0.82	0.66	-0.65	0.05		0.48	0.96	-0.4	-0.38	-0.49	-0.27	0.12	-0.47
Total Current Assets	0.99	0.89	-0.73	-0.44	0.0	-0.26	0.24	-0.61	0.48		0.66	0.52	0.05	0.4	0.59	0.38	0.45
Net Working Capital	0.61	0.63	-0.1	0.35	-0.69	0.46	-0.44	-0.18	0.96	0.66		-0.23	-0.23	-0.32	-0.08	0.27	-0.29
Common Stock	0.53	0.32	-0.69	-0.98	0.65	-0.69	0.67	-0.47	-0.4	0.52	-0.23		0.03	0.73	0.92	0.09	0.77
Net Receivables	0.13	0.39	-0.59	-0.19	0.53	-0.69	0.68	-0.5	-0.38	0.05	-0.23	0.03		0.39	0.09	0.22	0.38
Short Long Term Debt	0.46	0.39	-0.77	-0.82	0.85	-0.82	0.85	-0.36	-0.49	0.4	-0.32	0.73	0.39		0.78	0.36	1.0
Capital Stock	0.6	0.47	-0.75	-0.92	0.67	-0.67	0.71	-0.39	-0.27	0.59	-0.08	0.92	0.09	0.78		0.14	0.8
Short Term Debt	0.38	0.55	-0.48	-0.17	0.03	-0.32	0.32	-0.57	0.12	0.38	0.27	0.09	0.22	0.36	0.14		0.39
Current Deferred Revenue	0.51	0.43	-0.8	-0.85	0.83	-0.84	0.86	-0.43	-0.47	0.45	-0.29	0.77	0.38	1.0	0.8	0.39

Click cells to compare fundamentals

About NLS Pharmaceutics Financial Statements

NLS Pharmaceutics investors use historical fundamental indicators, such as NLS Pharmaceutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NLS Pharmaceutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	1.8 M	3.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for NLS Stock Analysis

When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC